Fortrea Holdings Inc. is a global contract research organization (CRO) providing comprehensive clinical development solutions to biopharmaceutical, biotechnology, and medical device companies worldwide. It specializes in Phase I through IV clinical trial management, clinical pharmacology, pharmacovigilance, regulatory affairs, data management, biostatistics, and consulting services across more than 20 therapeutic areas, including oncology, central nervous system disorders, rare diseases, and cell and gene therapies. The company operates through Clinical Services and Enabling Services segments, offering flexible delivery models such as full-service, functional service provider, and hybrid structures to streamline trial processes, optimize drug supply, and support patient dosing. Fortrea Holdings Inc. emphasizes innovation in decentralized trials, site partnerships, and technology integration to accelerate development timelines and enhance operational efficiency. Incorporated in 2023 and headquartered in Durham, North Carolina, it conducts operations in approximately 90 countries, partnering with sponsors to advance healthcare innovations from early-phase studies to post-approval support.